No Data
No Data
Express News | Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination With Tecentriq® in Extensive Stage Small Cell Lung Cancer
Genprex Gets Dosage Escalation Approval in Small-Cell Lung Cancer Treatment Trial; Shares Jump
Genprex Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination With Tecentriq in Extensive Stage Small Cell Lung Cancer
Express News | Genprex Inc -Received Letter From Nasdaq on Failure to Satisfy a Continued Listing Rule or Standard
Genprex Featured in CEO/CFO Magazine Discussing Novel Gene Therapies for Cancer and Diabetes
Press Release: Genprex Announces Formation of Mesothelioma Clinical Advisory Board
No Data
No Data